The report covers emerging Social Anxiety Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Social Anxiety Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Social Anxiety Disorder: An Overview
Social Anxiety disorder (SAD), also called Social Phobia, is the most common mental health condition that causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, and attending social gatherings, which can also affect day-to-day activities.
Social anxiety disorder can make a person fear being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them. Social anxiety is different from shyness, which is usually short-term and does not disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside their family.
As per DelveInsight, the Social Anxiety Disorder Market is anticipated to evolve immensely in the coming years owing to the increase in R&D activity, the rising prevalent population in the 7MM, the expected commercial success of upcoming therapies, and the rise in healthcare spending across the world. The current pipeline of social anxiety disorder consists of PH94B (Vistagen Therapeutics), EPI-CBD-001 (EmpowerPharm), (Bionomics), and others.
Social Anxiety Disorder Market Key Facts
According to the National Institute of Mental Health (NIMH), about 1 in 8 people (12.1%) experience Social Anxiety Disorder at some time in their life and in a given year. According to the US National Institutes of Health (NIH), SAD is the third most common psychiatric condition after depression and substance abuse. Of adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment.
As per the Anxiety and Depression Association of America (ADAA) 2021, social anxiety disorder affects around 15 million adults or 6.8% of the US population. Many people are frequently misdiagnosed as a result of the disease. thirty-six of people with social anxiety disorder experience symptoms for 10 years or more before seeking care, according to a 2007 ADAA survey.
According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated that the lifetime prevalence of Social anxiety disorder in the general population is close to 7%.
According to the National Institute of Health and Care Excellence (NICE), the lifetime prevalence of social anxiety disorder is 12% in the UK population.
As per Judith et. Al. (2017), the lifetime prevalence of Social Anxiety Disorder in Germany is found to be around 12%.
As per Lisa Fritscher (2021), the prevalence of Taijin kyofusho (a Japanese form of Social Phobia) in Japan is between 10-20% in the general population, and it is somewhat more common in men than women.
Social Anxiety Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Social Anxiety Disorder pipeline therapies. It also thoroughly assesses the Social Anxiety Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Social Anxiety Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Social Anxiety Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Social Anxiety Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Social Anxiety Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Social Anxiety Disorder Epidemiology, Segmented as –
12-month Diagnosed Prevalent Cases of Social Anxiety Disorder
Gender-specific Cases of Social Anxiety Disorder
Age-specific Cases of Social Anxiety Disorder
Severity-Specific Cases of Social Anxiety Disorder
Total Treated Cases of Social Anxiety Disorder
Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Social Anxiety Disorder market or expected to be launched during the study period. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Social Anxiety Disorder drugs based on their sale and market share.
The report also covers the Social Anxiety Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Social Anxiety Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Social Anxiety Disorder Market Will Evolve and Grow by 2032:
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market
Social Anxiety Disorder Therapeutics Analysis
Patients who manage their symptoms with psychological and pharmacologic treatment are more likely to achieve continued symptom-improvement benefits. SAD is typically treated on a long-term basis using US FDA-approved antidepressants with a sluggish onset of action (weeks) and limited therapeutic effects, as well as benzodiazepines, which are not FDA-approved for the treatment of SAD but are recommended for off-label usage.
Once the patient attains the desired therapeutic response, the medication should be continued for at least 12 months in order to prevent relapse. Selective Serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Gamma-aminobutyric acid (GABA), Beta-Blockers, and other anxiolytics are the standard drug classes used to treat SAD.
Social Anxiety Disorder Companies Actively Working in the Therapeutics Market Include
Vistagen Therapeutics
Bionomics
EmpowerPharm
And Many Others
Emerging and Marketed Social Anxiety Disorder Therapies Covered in the Report Include:
PH94B: Vistagen Therapeutics
BNC210: Bionomics
EPI-CBD-001: EmpowerPharm
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Social Anxiety Disorder Competitive Intelligence Analysis
4. Social Anxiety Disorder Market Overview at a Glance
5. Social Anxiety Disorder Disease Background and Overview
6. Social Anxiety Disorder Patient Journey
7. Social Anxiety Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Social Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Social Anxiety Disorder Unmet Needs
10. Key Endpoints of Social Anxiety Disorder Treatment
11. Social Anxiety Disorder Marketed Therapies
12. Social Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances
13. Social Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Social Anxiety Disorder Market Outlook (In US, EU5, and Japan)
16. Social Anxiety Disorder Companies Active in the Market
17. Social Anxiety Disorder Access and Reimbursement Overview
18. KOL Views on the Social Anxiety Disorder Market
19. Social Anxiety Disorder Market Drivers
20. Social Anxiety Disorder Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Follicular Lymphoma Market
“Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Follicular Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Follicular Lymphoma market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/oncology
